An interventional study of Transcutaneous spinal cord stimulation and Sham transcutaneous spinal cord stimulation in Hereditary Spastic Paraplegias, Spinocerebellar Ataxia and Spastic Ataxia, sponsored by University of Washington. Enrolling by invitation at 1 site in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by University of Washington · Not applicable, Interventional, and Treatment
Among 18 studies in Spastic Paraplegia, Hereditary with a site in United States — 7 open to participants now, 10 under way, none of them phase 3. Spastic Paraplegia, Hereditary · United States.
Among the 18 studies in Spastic Paraplegia, Hereditary with a site in United States, this one is one of 3 that started in 2026, is one of 3 with no phase, and was the 18th registered.
50 studies on the registry are indexed under Spastic Paraplegia, Hereditary; 19 are open to participants now.
Browse Spastic Paraplegia, Hereditary studies →7 of the 18 studies in Spastic Paraplegia, Hereditary with a site in United States are open now. Recruiting first, the newest first:
Rahul Sachdeva · Sites in United States
Ages 18+
Boston Children's Hospital · Sites in United States
University of California, San Diego · Sites in United States
Boston Children's Hospital · Sites in United States
Ages 1 mo–30 yrs
Boston Children's Hospital · Sites in United States
Ages up to 30 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 17 Spastic Paraplegia, Hereditary studies recruiting now, 10 (59%) set no upper age limit and 7 (41%) stop at 75 or younger; 13 take children under 18; 3 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 2 · Phase 4 1
First in 2001; this study’s year is marked. 3 started in 2026.
This study's planned enrollment of 4 is below the median of 25 across 24 interventional studies indexed under Spastic Paraplegia, Hereditary.
Median enrollment 9 across the 7 interventional studies, 200 across the 11 observational. Of the 8 that completed or were terminated, 2 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 18 have an industry lead sponsor. The 10 most frequent:
University of Washington is the lead sponsor of 1,434 studies on the registry; 226 are open to participants now.
Of its 158 completed or terminated interventional studies of FDA-regulated products, 136 (86%) have results posted.
University of Washington has 1 study filed under Spastic Paraplegia, Hereditary — fewer than ten, so there is no comparison to draw.
3 of the studies in Spastic Paraplegia, Hereditary with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05848271University of California, San DiegoNatural History Study of Patients with HPDL Mutations | 2026-12-31 |
| NCT05354622Boston Children's HospitalHereditary Spastic Paraplegia Genomic Sequencing Initiative (HSPseq) | 2027-04-29 |
| NCT07930481University of WashingtonNon-invasive Spinal Stimulation for Gait in Genetic Spasticity | 2027-06 |
Add all 3 to your calendar (.ics) → With an account.
Among the 18 studies in Spastic Paraplegia, Hereditary with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This trial is a double-blind, crossover, sham-controlled pilot study to evaluate the feasibility, safety, and preliminary efficacy of repeated transcutaneous spinal cord stimulation (tSCS) over the lower thoracic and upper lumbar spinal segments in adults with hereditary spastic paraplegias (HSPs) and other genetic causes of spasticity. The investigators will recruit four people with hereditary lower extremity spasticity who are able to ambulate with or without assistive devices to participate in the trial. The investigators will assess a range of outcome measures to evaluate tSCS in this patient population and to inform the design of a larger study.
Potential participants will be screened for study inclusion. Enrollees will undergo baseline testing, including clinical assessments, neurophysiological tests, and questionnaires. Participants will then undergo a four-week block of intensive locomotor training with a physical therapist with either active or sham spinal cord stimulation. During each block, participants will complete three sessions of training with active or sham stimulation per week for four weeks. The assessment battery will be completed at the beginning, midpoint, and end of the block. Participants will then undergo a 4-week "washout" block without stimulation or intensive therapy (although they are welcome to continue outside physical therapy and exercise), followed by another 4-week block with intensive training and either sham or active stimulation. Like the first block, the investigators will complete the battery of assessment measures at the beginning, midpoint, and end of the block. The investigators will also complete follow-up assessments four weeks after the completion of this second block.
The main questions this study hopes to answer are:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will undergo intensive locomotor training combined with sham stimulation
Device: Sham transcutaneous spinal cord stimulation
Participants will undergo active stimulation combined with intensive locomotor training.
Device: Transcutaneous spinal cord stimulation
Participants will undergo intensive locomotor training combined with transcutaneous spinal cord stimulation at T11-L1 level.
Participants will undergo intensive locomotor training combined with sham transcutaneous spinal cord stimulation at T11-L1 level.
Spastic Paraplegia Rating Scale (SPRS)
This is a 13-point clinical scale that assesses the severity of symptoms attributable to hereditary spastic paraplegia. Scores range from 0 (no impairment) to 52 (severe impairment).
Time frame: This assessment will be performed at baseline, and again at weeks 2, 4, 8, 10, 12, and 16.
Lower extremity dynamometry
This is a qantitative assessment of force generated by the muscles of the lower extremity, measured in Newtons.
Time frame: This assessment will be performed at baseline, and again at weeks 4, 8, 12, and 16.
25-foot timed walk test
This is a quantitative assessment of mobility and leg function that measures the time it takes an individual to safely and quickly walk a distance of 25 feet.
Time frame: This assessment will be performed at baseline, and again at weeks 2, 4, 8, 10, 12, and 16.
2-minute walk test
This is a clinical functional assessment that measures the maximum distance a person can walk on a flat, hard surface in two minutes. Assesses self-paced walking ability, functional endurance, and aerobic capacity.
Time frame: This assessment will be performed at baseline, and again at weeks 2, 4, 8, 10, 12, and 16.
Hmax/Mmax ratio
This is an electrophysiological quantification of spasticity.
Time frame: This assessment will be performed at baseline, and again at weeks 2, 4, 8, 10, 12, and 16.
Mini-Balance Evaluation Systems Test (Mini-BEST)
This is a clinical assessment of balance performed by a physical therapist. Scores range from 0 (severe balance impairment) to 28 (no balance impairment).
Time frame: This assessment will be performed at baseline, and again at weeks 4, 8, 12, and 16.
Patient Global Impression of Change (PGIC)
This is a short, patient-reported outcome measure used in clinical trials and medical practice to evaluate how much a patient's condition has changed since the start of treatment. Scores range from 1 (very much improved) to 7 (very much worsened).
Time frame: This assessment will be performed at baseline, and again at weeks 4, 8, 12, and 16.
Clinician Global Assessment of Change (CGIC).
This is a clinician-reported outcome measure used in clinical trials and medical practice to evaluate how much a patient's condition has changed since the start of treatment. Scores range from 1 (very much improved) to 7 (very much worsened).
Time frame: This assessment will be performed at baseline, and again at weeks 4, 8, 12, and 16.
Neuropathic Bladder Symptom Score (NBSS)
This is a validated, patient-reported outcome measure, designed to evaluate urinary symptoms, complications, and quality of life in individuals with neurogenic lower urinary tract dysfunction. Scores range from 0 (no symptoms) to 74 (severe symptoms).
Time frame: This assessment will be performed at baseline, and again at weeks 4, 8, 12, and 16.
Neuropathic Bowel Dysfunction Scale (NBDS)
This is a 10-item clinical questionnaire used to evaluate bowel symptoms, track treatment effectiveness, and measure quality of life in patients with neurogenic bowel conditions. Scores range from 0 (no symptoms) to 47 (severe symptoms).
Time frame: This assessment will be performed at baseline, and again at weeks 4, 8, 12, and 16.
Neuropathic Pain Symptom Inventory (NPSI)
This is a self-administered, 12-item clinical questionnaire designed to evaluate and quantify the specific symptoms of peripheral and central neuropathic pain. Scores range from 0 (no pain) to 100 (worst pain imaginable).
Time frame: This assessment will be performed at baseline, and again at weeks 4, 8, 12, and 16.
Patient Reported Outcome Measurement Information Systems (PROMIS) Item Bank v1.0 - Pain Interference - Short Form 8a
This is an 8-point patient-reported questionnaire that measures how much pain hinders a person's physical, mental, emotional, social, and recreational activities over the past 7 days. Scores range from 8 (not at all) to 40 (very much).
Time frame: This assessment will be performed at baseline, and again at weeks 4, 8, 12, and 16.
Modified Ashworth Scale (MAS)
This is a clinical assessment used to quantify muscle tone and resistance to passive movement in neurological conditions. Raters will assess spasticity with hip flexion, hip extension, hip adduction, hip internal rotation, hip external rotation, knee flexion, knee extension, and plantarflexion. For each joint tested, scores range form 0 (no spasticity) to 4 (severe spasticity).
Time frame: This assessment will be performed at baseline, and again at weeks 2, 4, 8, 10, 12, and 16.
Plan to share: No — We do not currently have plans to share individual patient data with other researchers. Data may be available upon request as appropriate.
Start is estimated for Nov 2026; primary completion for Jun 2027, 7 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Spastic Paraplegia, Hereditary →